TB-201 / Therabest, Peptron - LARVOL DELTA

Targeting the non-canonical immune checkpoint MUC1-C enhances anti-PD-1 therapy in solid tumors (AACR 2026) - "Ongoing studies are evaluating the combinatory efficacy of additional anti-MUC1 antibodies and ICIs to further define the selective advantages of PAb001 in treating malignant tumors, and are also aimed at elucidating the molecular mechanisms underlying its therapeutic activity. In conclusion, these findings support the therapeutic potential of a dual-checkpoint blockade strategy that concurrently targets canonical and non-canonical pathways, which offers a promising approach to address limitations inherent to current ICI-based therapies."

Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • MUC1